EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models

Varsha Ananthapadmanabhan, Simone Bruno, Leonard Vonk, Yu-Chen Cheng, Abeba Teshager, Benjamin K Eschle, Charles L Howarth, Joana S Rodrigues, Julia Schnabel, Ananya Kodali, Prafulla C Gokhale, Rujuta Kshirsagar und 9 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci199049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Varsha Ananthapadmanabhan und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Tumor Suppressor Protein p53, Carcinoma, Merkel Cell, Signal Transduction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, US Public Health Service, The Bridge Project, a partnership between the Koch Institute for Integrative Cancer Research at MIT and Harvard Cancer Consortium.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MDM2 is transcriptionally activated by the ST-MYCL-Tip60 complex in virus-positive Merkel cell carcinoma (MCC). MDM2 suppresses p53 and is a rational therapeutic target. MDM2 inhibitors face an intrinsic limitation: p53 activation induces MDM2 transcription, creating a feedback loop that blunts inhibitor efficacy. We demonstrate that MDM2 degraders KTX-049 and KT-253 overcome this limitation by collapsing the p53/MDM2 negative feedback loop. KTX-049 was >100-fold more potent than the MDM2 inhibitor DS-3032 across WT p53 MCC cell lines, and this superior potency was quantitatively supported by mechanistic mathematical modeling. In vivo, KT-253 produced deep and durable tumor regressions, including complete responses in patient-derived xenograft models. Acquired resistance was strongly associated with acquisition of TP53 mutations, confirming on-target pathway pressure. These findings establish feedback architecture as a critical determinant of therapeutic response and position MDM2 degradation as a qualitatively distinct strategy that produces more durable pathway engagement than MDM2 inhibition, providing a preclinical rationale for prioritizing MDM2 degraders in WT TP53 MCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Carcinoma, Merkel CellSignal TransductionFeedback, PhysiologicalSkin NeoplasmsNeoplasm ProteinsHumansAnimalsMiceCell Line, TumorNon-Melanoma Skin NeoplasmsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

ApoptosisCell biologyOncologyTherapeuticsp53

Substanzen

Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53MDM2 protein, humanTP53 protein, humanNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA.
  • The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

Förderung

  • NCI NIH HHS
  • US Public Health Service
  • The Bridge Project, a partnership between the Koch Institute for Integrative Cancer Research at MIT and Harvard Cancer Consortium

Zitieren

APA

Ananthapadmanabhan, V., Bruno, S., Vonk, L., Cheng, Y. C., Teshager, A., Eschle, B. K., Howarth, C. L., Rodrigues, J. S., Schnabel, J., Kodali, A., Gokhale, P. C., Kshirsagar, R., Breitkopf, S. B., Sharma, K., Paulo, J. A., Li, Y., Cherniack, A. D., Michor, F., Chutake, Y., …, & DeCaprio, J. A. (2026). Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models. Journal of Clinical Investigation. https://doi.org/10.1172/jci199049

Vancouver

Ananthapadmanabhan V, Bruno S, Vonk L, Cheng YC, Teshager A, Eschle BK, et al. Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models. Journal of Clinical Investigation. 2026. doi:10.1172/jci199049

BibTeX
@article{Ananthapadmanabhan2026,
  author = {Ananthapadmanabhan, Varsha and Bruno, Simone and Vonk, Leonard and Cheng, Yu-Chen and Teshager, Abeba and Eschle, Benjamin K and Howarth, Charles L and Rodrigues, Joana S and Schnabel, Julia and Kodali, Ananya and Gokhale, Prafulla C and Kshirsagar, Rujuta and Breitkopf, Susanne B and Sharma, Kirti and Paulo, Joao A and Li, Yvonne and Cherniack, Andrew D and Michor, Franziska and Chutake, Yogesh and Dey, Joyoti and DeCaprio, James A},
  title = {Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci199049}
}
Kostenlos starten →